All In Biotech

Drug Trial Radar · NCT05797168

Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors

A Modular Phase I/IIa, Open-label Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Ascending Doses of AZD5335 Monotherapy and in Combination With Anti-cancer Agents in Participants With Solid Tumors

Last checked: Nov 19, 2026Latest source record: Oct 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 622 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

622

Planned (sponsor's estimate)

Start

Jun 5, 2023

Primary completion

Aug 4, 2028

Study completion Aug 4, 2028

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
Apr 4, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 130 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This research is designed to determine if experimental treatment with Antibody-drug conjugate, AZD5335, alone, or in combination with anti-cancer agents is safe, tolerable, and has anti-cancer activity in patients with advanced tumors

Conditions

  • Ovarian Cancer
  • Lung Adenocarcinoma
  • Endometrial Cancer
  • Lung Squamous Cell Carcinoma

Interventions

  • Torvutatug samrotecanDrug

    IV Antibody-drug conjugate

  • SaruparibDrug

    Oral PARP inhibitor

  • BevacizumabDrug

    IV Monoclonal antibody

  • CarboplatinDrug

    IV Alkylating agent

  • PalacaparibDrug

    Oral PARP inhibitor

  • PembrolizumabDrug

    IV Biologic

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with adverse events/serious adverse eventsTime frame: From time of Informed Consent to 30 days post last dose.
  2. The number of participants with dose limiting toxicity(DLT), as defined in the protocolTime frame: From the first dose of torvu-sam on Cycle 1 Day 1 up to and including the planned end of Cycle 1 (At the end of 21 days)

Locations

60 sites in 12 countries. Site status is shown where the registry gives one.

  • Research Site

    Duarte, California · Recruiting

  • Research Site

    Irvine, California · Recruiting

  • Research Site

    La Jolla, California · Withdrawn

  • Research Site

    Aurora, Colorado · Recruiting

  • Research Site

    Louisville, Kentucky · Terminated

  • Research Site

    Boston, Massachusetts · Recruiting

  • Research Site

    Detroit, Michigan · Recruiting

  • Research Site

    Columbus, Ohio · Recruiting

  • Research Site

    Portland, Oregon · Recruiting

  • Research Site

    Providence, Rhode Island · Recruiting

  • Research Site

    Providence, Rhode Island · Withdrawn

  • Research Site

    Houston, Texas · Recruiting

  • Research Site

    Fairfax, Virginia · Recruiting

  • Research Site

    Liverpool, Australia · Recruiting

  • Research Site

    Melbourne, Australia · Recruiting

  • Research Site

    Edmonton, Alberta, Canada · Recruiting

  • Research Site

    London, Ontario, Canada · Recruiting

  • Research Site

    Toronto, Ontario, Canada · Recruiting

  • Research Site

    Montreal, Quebec, Canada · Recruiting

  • Research Site

    Montreal, Quebec, Canada · Recruiting

  • Research Site

    Chengdu, China · Recruiting

  • Research Site

    Chongqing, China · Recruiting

  • Research Site

    Guangzhou, China · Recruiting

  • Research Site

    Guangzhou, China · Recruiting

  • Research Site

    Jinan, China · Recruiting

  • Research Site

    Xi'an, China · Recruiting

  • Research Site

    Zhengzhou, China · Terminated

  • Research Site

    Berlin, Germany · Recruiting

  • Research Site

    Essen, Germany · Recruiting

  • Research Site

    Freiburg im Breisgau, Germany · Recruiting

  • Research Site

    Hanover, Germany · Recruiting

  • Research Site

    Leipzig, Germany · Recruiting

  • Research Site

    Mannheim, Germany · Recruiting

  • Research Site

    Regensburg, Germany · Recruiting

  • Research Site

    Haifa, Israel · Recruiting

  • Research Site

    Ramat Gan, Israel · Recruiting

  • Research Site

    Hidaka-shi, Japan · Recruiting

  • Research Site

    Kashiwa, Japan · Recruiting

  • Research Site

    Kōtoku, Japan · Recruiting

  • Research Site

    Sunto-gun, Japan · Recruiting

Showing 40 of 60 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.